© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Prostate Cancer
Assay Shows Value for Patients With Low-Risk Prostate Cancer
May 25, 2020
Aaron E. Katz, MD, discusses a genomic test for patients with low-risk prostate cancer.
Tweet Chat Recap: Sequencing Strategies for a Post-Docetaxel Patient with Metastatic Castration-Resistant Prostate Cancer
May 21, 2020
In an interview with Targeted Oncology, following a tweet chat on prostate cancer, Tian Zhang, MD, discussed the key takeaways from the tweet chat discussion and highlighted both the role of molecular testing and the impact of the recent FDA approvals in prostate cancer.
FDA Approves CDx Tests for Olaparib in HRR-Mutant mCRPC
May 20, 2020
Two companion diagnostic assays were granted FDA approval to identify male patients with metastatic castration-resistant prostate cancer who are eligible for treatment with olaparib.
FDA Approves Olaparib for HRR-Mutant mCRPC
May 19, 2020
The FDA has approved olaparib for the treatment of patients with metastatic castration-resistant prostate cancer who have deleterious or suspected deleterious germline or somatic HRR gene mutations and have progressed following prior treatment with a new hormonal agent.
Rucaparib Induces Responses in Men With Metastatic Castration-Resistant Prostate Cancer
May 19, 2020
“Although PARP inhibitor treatment has demonstrated radiographic and PSA responses in patients with BRCA alterations (4–8), the data presented here offer compelling evidence that response to PARP inhibitors is limited in men with mCRPC harboring an ATM, CDK1/2, or CHEK2 alteration."
Patient-Reported Outcomes From the CARD Trial Favor Cabazitaxel for Treating mCRPC
May 16, 2020
Cabazitaxel demonstrated better patients-reported outcomes compared with either abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer.
Clinical Activity With Pembrolizumab/Enzalutamide Emboldens Further Study in mCRPC
May 15, 2020
Positive safety and efficacy outcomes were witnessed in the KEYNOTE-365 study , supporting further assessment of the combination of pembrolizumab and enzalutamide in a larger population of patients with metastatic castration resistance prostate cancer.
FDA Approves Rucaparib for BRCA1/2-Mutant mCRPC
May 15, 2020
"Rucaparib’s approval could have a profound impact on patients with BRCA2 and BRCA1 mutations, who have no other targeted treatment option available to them based on this mutation."
Neoadjuvant Apalutamide Leads to Reduced Tumor Volume in High-Risk Prostate Cancer
May 15, 2020
"Historically, neoadjuvant hormone therapy has been shown to improve pathologic outcomes. Therefore, neoadjuvant androgen deprivation therapy may allow a nerve-sparing surgical approach to increase post-surgical quality-of-life outcomes without compromising oncologic outcomes.”
Darolutamide Shows OS Benefit With ADT in Updated ARAMIS Trial Findings in Prostate Cancer
May 15, 2020
A significant improvement in overall survival was observed with darolutamide plus androgen deprivation therapy compared with androgen deprivation therapy alone in men with non-metastatic castration-resistant prostate cancer treated in the phase III ARAMIS trial.